Skip to content

Icosapent Ethyl

Also called Vascepa

Purified EPA ethyl ester with NO DHA. The DHA-free formulation matters: mixed EPA/DHA products raise LDL, and the trials that succeeded used EPA alone.

  • TypeSmall molecule
  • FormOral
  • Researched forLongevity

Where to get Icosapent Ethyl

AlgoRx
Oral
Code CAMERON

Prescription route: a licensed provider decides whether it fits you.

Shop oral at AlgoRx

The short version

  • Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
  • What the evidence isApproved on the strength of REDUCE-IT (8,179 patients), which showed a 25% reduction in major cardiovascular events in statin-treated patients with elevated triglycerides.
  • What to watchPalpitations or an irregular, racing pulse.

How Icosapent Ethyl works

Icosapent ethyl is the ethyl ester of eicosapentaenoic acid and nothing else — no DHA, no mixed marine oil. That purity is the product, and the reason it matters is a shape argument about membranes.

The triglyceride-lowering mechanism is separate and less contested. EPA is a weak PPAR-alpha ligand, it inhibits diacylglycerol acyltransferase, and it reduces hepatic very-low-density lipoprotein secretion while increasing lipoprotein lipase activity.

  • Oral

On the goal map: The unglamorous evidence — what actually has mortality data (Longevity & healthspan)

Research on Icosapent Ethyl7 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Human clinical evidence

  • Approved on the strength of REDUCE-IT (8,179 patients), which showed a 25% reduction in major cardiovascular events in statin-treated patients with elevated triglycerides. That is a large effect for an add-on therapy.

  • The result is contested in a specific and important way. The placebo was mineral oil, and LDL and hsCRP *rose* in the placebo arm — raising the possibility that part of the benefit reflects placebo harm rather than drug benefit. The STRENGTH trial, using a different omega-3 formulation and a corn oil placebo, found no benefit at all.

  • Two trials, two placebos, two answers. Anyone presenting this as settled in either direction is not reading it carefully.

Correlative data

  • Wide prescribing since approval. Atrial fibrillation appears more often on it across trials, and bleeding risk is modestly increased — both consistent and both worth knowing.

How the mechanism reads

  • Purified EPA only, with no DHA — which is the design decision that distinguishes it from every fish oil product. DHA raises LDL; EPA does not.

    Mechanistic
  • EPA reduces triglycerides by decreasing hepatic VLDL production, and has membrane-stabilizing and anti-inflammatory effects independent of lipids.

    Mechanistic
  • The triglyceride reduction is too small to explain a 25% event reduction, which is why the mechanism is thought to be membrane and inflammatory — and also why the mineral-oil critique cannot simply be dismissed.

    Mechanistic

Sources

  • Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine 2019 · PMID 30415628
  • Curfman G, et al. Icosapent ethyl: scientific and legal controversies. Open Heart 2021 · PMID 33888593
  • Zhang W, et al. Unraveling the discrepancies between REDUCE-IT and STRENGTH trials with omega-3 fatty acids: new analytical approaches. Frontiers in Nutrition 2024 · PMID 39758310
  • Huh JH, et al. Omega-3 fatty acids and atrial fibrillation. Korean Journal of Internal Medicine 2023 · PMID 36514212
  • Verma S, et al. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation 2021 · PMID 34710343
  • Sherratt SCR, et al. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current Atherosclerosis Reports 2023 · PMID 36580204

Icosapent Ethyl safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Atrial fibrillation or flutter history, because omega-3 at this level raised it in trials.
  • Bleeding disorders, or anticoagulant and antiplatelet use.
  • Fish or shellfish allergy.
  • Severe liver impairment, as EPA ester processing is hepatic.
  • Pregnancy, unless the benefit clearly outweighs unknowns.

What’s expected

  • Triglycerides fall, with the cardiovascular benefit seen in REDUCE-IT.
  • Joint aches, constipation or fishy burps.
  • A small rise in atrial fibrillation risk and in minor bleeding.

Watch for

  • Palpitations or an irregular, racing pulse.
  • Black stools or blood in vomit.
  • Bruising or nosebleeds that are new.

Labs that tell you it’s working

  • Lipid Panel: triglycerides are the labeled target, and LDL should not rise because it has no DHA.
  • hs-CRP: the trial population was selected for inflammatory and lipid risk.
  • ApoB: tracks particle count independent of triglycerides.

Purified EPA ethyl ester with no DHA: lowers triglycerides and cardiovascular events, but raises atrial fibrillation and bleeding risk. PMID 36514212 PMID 30415628 PMID 39758310

Bloodwork to runHow you would know it is working: 7 tests in one order, code CAMERON

Icosapent Ethyl FAQ4 common questions

Is Icosapent Ethyl approved for human use?
No. Icosapent Ethyl is a research compound.
What is Icosapent Ethyl researched for?
Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Which labs show whether it's doing anything?
Lipid Panel; hs-CRP; ApoB: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Icosapent Ethyl: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Icosapent Ethyl is. Skool covers how it is run.

Free on this page

What Icosapent Ethyl is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Icosapent Ethyl is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool